患有非酒精性脂肪性肝病的患者免疫特征的不同方面
H A Osman1, M Tag-Adeen2, U M Abdelaal3
1Department of Tropical Medicine and Gastroenterology, Qena Faculty of Medicine, South Valley University, Qena, Egypt.
这项研究发现,非酒精性脂肪肝疾病 (NAFLD) 患者的免疫球蛋白A (IgA),免疫球蛋白G (IgG),补充C3和补充C4水平升高. 这些免疫标志物可能在NAFLD发展和纤维化进展中发挥作用.
科学领域:
- 免疫学 免疫学 免疫学
- 肝病学 肝病学是一种肝病学.
- 临床生物化学 临床生物化学
背景情况:
- 非酒精性脂肪肝 (NAFLD) 影响全球人口的很大一部分.
- 目前尚不完全了解NAFLD病原体的确切机制.
- 免疫系统组件,如补剂和免疫球蛋白在NAFLD中的作用需要进一步研究.
研究的目的:
- 研究免疫球蛋白 (IgA,IgG,IgM) 和补充因子 (C3,C4) 的血清水平与NAFLD的发病因子之间的关联.
- 将NAFLD患者的免疫学概况与健康对照者的免疫学概况进行比较.
主要方法:
- 招募了200名参与者的队列,包括100名NAFLD患者和100名健康对照.
- 根据欧洲肝脏研究协会 (EASL) 2022年指南,使用非侵入性方法确立了NAFLD诊断.
- 所有参与者的IgA,IgG,IgM,C3和C4血清水平都得到量化.
主要成果:
- 与健康对照组相比,NAFLD患者的IgA平均水平显著更高 (4.20±5.07对2.22±1.05,P=0.000).
- 在NAFLD患者中观察到显著升高的IgG水平 (17.08±3.87与11.59±3.34,P<0.001),C3 (1.28±0.61与0.90±0.27,P<0.001) 和C4 (0.40±0.19与0.30±0.12,P<0.001).
- 在IgM水平方面没有报告显著差异 (数据未显示在摘要中).
结论:
- 在NAFLD患者中存在IgA,IgG,C3和C4的血清水平升高.
- 这些免疫学变化可能与脂肪肝疾病的发展和进展有关.
- 这些发现表明,这些免疫标志物在NAFLD的发病和纤维化进展中可能发挥作用.
更多相关视频
08:41Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
相关概念视频
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can also...
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Cirrhosis I: Introduction
